---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-26-000020"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T01:56:46.460654+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Charles River Labs Q4 revenue $994M, GAAP loss $5.62; sees 2026 non-GAAP EPS $10.70-$11.20

## Summary
- Q4 GAAP loss per share $(5.62) from $994.2M revenue (-0.8% YoY); non-GAAP EPS $2.39 (-10.2%).
- FY2025 revenue $4.02B (-0.9%); GAAP loss $(2.91)/share; non-GAAP EPS $10.28 (-0.4% vs $10.32).
- DSA organic revenue -3.3% in Q4; CEO cites robust DSA net bookings and cautious optimism for demand recovery.
- 2026 organic revenue guidance (1.0)% to flat; non-GAAP EPS $10.70-$11.20 implies 4-9% growth.
- Recorded $211M intangible and $165M goodwill impairments in Biologics Solutions (Manufacturing segment).

## SEC filing metadata
- accession: 0001100682-26-000020
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000020/0001100682-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068226000020/crl-20260218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-26-000020
- JSON: https://secwatch.observer/filing/0001100682-26-000020.json
- Plain text: https://secwatch.observer/filing/0001100682-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.